- Home
- BBIO vs INM Comparison
BBIO vs INM Comparison
Compare BBIO & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- INM
- Stock Information
- Founded
- BBIO 2015
- INM 1981
- Country
- BBIO United States
- INM Canada
- Employees
- BBIO N/A
- INM N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- BBIO Health Care
- INM Health Care
- Exchange
- BBIO Nasdaq
- INM Nasdaq
- Market Cap
- BBIO 9.4B
- INM 5.1M
- IPO Year
- BBIO 2019
- INM N/A
- Fundamental
- Price
- BBIO $55.98
- INM $2.11
- Analyst Decision
- BBIO Strong Buy
- INM
- Analyst Count
- BBIO 16
- INM 0
- Target Price
- BBIO $64.44
- INM N/A
- AVG Volume (30 Days)
- BBIO 2.2M
- INM 127.6K
- Earning Date
- BBIO 11-11-2025
- INM 11-13-2025
- Dividend Yield
- BBIO N/A
- INM N/A
- EPS Growth
- BBIO N/A
- INM N/A
- EPS
- BBIO N/A
- INM N/A
- Revenue
- BBIO $235,812,000.00
- INM $4,942,633.00
- Revenue This Year
- BBIO $115.46
- INM N/A
- Revenue Next Year
- BBIO $65.03
- INM N/A
- P/E Ratio
- BBIO N/A
- INM N/A
- Revenue Growth
- BBIO 7.62
- INM 7.50
- 52 Week Low
- BBIO $21.72
- INM $1.72
- 52 Week High
- BBIO $56.24
- INM $8.27
- Technical
- Relative Strength Index (RSI)
- BBIO 64.02
- INM 42.17
- Support Level
- BBIO $52.97
- INM $2.17
- Resistance Level
- BBIO $55.33
- INM $2.50
- Average True Range (ATR)
- BBIO 1.56
- INM 0.13
- MACD
- BBIO 0.26
- INM -0.00
- Stochastic Oscillator
- BBIO 96.51
- INM 15.22
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.